27,276 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Bought by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG purchased a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,276 shares of the company's stock, valued at approximately $701,000.

Several other hedge funds have also made changes to their positions in the business. Rhumbline Advisers grew its stake in IDEAYA Biosciences by 0.5% during the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after purchasing an additional 585 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after acquiring an additional 853 shares in the last quarter. Assetmark Inc. lifted its stake in IDEAYA Biosciences by 2.5% in the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after acquiring an additional 1,084 shares during the last quarter. R Squared Ltd purchased a new position in IDEAYA Biosciences in the fourth quarter worth approximately $35,000. Finally, NEOS Investment Management LLC grew its holdings in IDEAYA Biosciences by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 16,066 shares of the company's stock worth $413,000 after acquiring an additional 1,577 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Down 7.1 %

NASDAQ:IDYA traded down $1.13 during midday trading on Thursday, reaching $14.65. The stock had a trading volume of 315,485 shares, compared to its average volume of 910,681. The stock has a market cap of $1.28 billion, a P/E ratio of -4.45 and a beta of 0.51. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42. The firm has a fifty day simple moving average of $19.17 and a two-hundred day simple moving average of $24.50.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analysts' expectations of $7.00 million. On average, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IDYA. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Stephens reaffirmed an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Wedbush reiterated an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.